CoChat
Sign Up
Cited by 54Venous Thromboembolism Diagnosis and ManagementBariatric Surgery and OutcomesBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial

Steele, Kimberley E., Canner, Joseph, Prokopowicz, Gregory, Verde, Franco, Beselman, Aleksandra, Wyse, Ransom, Chen, Junnan, Streiff, Michael, Magnuson, Thomas, Lidor, Anne, Schweitzer, Michael·2015·Surgery for Obesity and Related Diseases
DOI 10.1016/j.soard.2014.10.003
Open this paper in CoChat — free account

Abstract

Background Prophylaxis for venous thromboembolism is routinely performed for all patients undergoing bariatric surgery. However, there is disagreement regarding the optimal dosing and duration of anticoagulant therapy. Furthermore, there is little data regarding the incidence of asymptomatic deep venous thrombosis (DVT) in this population. Our objective was to conduct a pilot randomized double blind study to evaluate the pharmacodynamic parameters of 2 different anticoagulation medications (enoxaparin and fondaparinux) administered to patients undergoing bariatric surgery.Methods From July 2010 to August 2013, 198 consecutive bariatric surgery patients from an academic institution were randomized in a double blinded manner to receive either 40 mg enoxaparin twice daily or 5mg fondaparinux sodium once daily. Antifactor Xa activity was measured on all patients in both study arms, 3 hours after the first dose (on the day of the operation), immediately before the second dose (postoperative day one), and 3 hours after the second dose. At the routine 2 week postoperative visit, patients underwent magnetic resonance venography (MRV) to detect DVT. The primary outcome was attainment of therapeutic antifactor Xa levels. The secondary outcome was DVT, as detected by MRV. Safety outcomes were perioperative bleeding, perioperative complications, and death.Results Of 198 patients randomized, 177 underwent MRV and 137 had interpretable antifactor Xa levels. Nearly half of the patients (47.4%) did not attain target prophylactic antifactor Xa levels. Adequate antifactor Xa levels were more common with fondaparinux (74.2%) than with enoxaparin (32.4%). Antifactor Xa levels were also associated with preoperative D-dimer level. 4 of the 175 patients who underwent MRV developed DVT, 2 in each arm of the study. No major adverse events occurred in either arm.Conclusion Fondaparinux was much more likely to produce target prophylactic antifactor Xa levels than enoxaparin. Both regimens appear to be equally effective at reducing the risk of DVT. Further prospective studies are needed to determine the optimal DVT prophylaxis regimen in the bariatric surgical population.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.soard.2014.10.003

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Steele, K. E., Canner, J., Prokopowicz, G., Verde, F., Beselman, A., Wyse, R., Chen, J., Streiff, M., Magnuson, T., Lidor, A., & Schweitzer, M.
Affiliations
Johns Hopkins University (US)
Corresponding author
Steele, Kimberley E.
ORCID
Venue
Surgery for Obesity and Related Diseases
Publisher
Elsevier BV
Published
2015-05
Volume
11
Issue
3
Pages
672-683
ISSN
1550-7289 (ISSN-L)
DOI
10.1016/j.soard.2014.10.003
OpenAlex
W2094600116
Cited by
54
References
44
Citations by year
2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 11 · 2018: 2 · 2017: 6 · 2016: 3 · 2015: 3
FWCI
3.13
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Surgery for Obesity and Related Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
bariatric surgery, thromboprophylaxis
MeSH terms
Fondaparinux, Adolescent, Adult, Aged, Anticoagulants, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Obesity, Morbid, Pilot Projects, Polysaccharides, Postoperative Care, Postoperative Complications, Preoperative Care, Prospective Studies, Treatment Outcome, Enoxaparin, Bariatric Surgery, Venous Thromboembolism, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review